Navigation Links
Peregrine Pharmaceuticals to Report First Quarter FY 2009 Financial Results
Date:9/3/2008

TUSTIN, Calif., Sept. 3 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it will release its financial results for the first quarter of fiscal year 2009 on September 9, 2008 at 7:00 a.m. EDT and will host a conference call and webcast to discuss the results at 11:30 a.m. EDT on the same day.

Peregrine's senior management will discuss financial results for the first quarter ended July 31, 2008 and will review recent operating highlights. A question-and-answer session will follow management's discussion. All interested parties are encouraged to listen to the live conference call or the archived webcast.

The conference call and webcast will begin at 11:30 a.m. EDT/ 8:30 a.m. PDT. To listen to a live broadcast of the call over the Internet or to review the archived webcast, please visit: http://www.peregrineinc.com. The webcast will be archived on Peregrine's website for 30 days.

To listen to the conference call via telephone, please call the following number approximately 10 minutes prior to the scheduled start time and request to join the Peregrine Pharmaceuticals call: (800) 860-2442. A telephonic replay of the conference call will be available starting approximately one hour after the conclusion of the call through September 16, 2008 by calling (877) 344-7529, passcode 382933#.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead pro
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... BROOK, N.Y. , May 4, 2015 /PRNewswire/ ... a $250,000 cooperative research and development agreement (CRADA) ... to advance the development of TRB-N0224 for the ... animals, including dogs and cats.  Traverse Biosciences has ... TRB-N0224 for the treatment and control of periodontal ...
(Date:5/4/2015)... 04, 2015 Genedata, a leading ... and life science research, today announced the release ... version of its enterprise solution for biologics R&D. ... more efficient discovery and development of novel biotherapeutics. ... and address protein optimization and developability requirements. Genedata ...
(Date:5/4/2015)... May 4, 2015 - New ... med students prepare for the United States Medical Licensing ... of scientific, technical and medical information products and services, ... (Massive Open Online Course) designed to help medical students ... Step 1, the first and most daunting of the ...
(Date:5/4/2015)... 04, 2015 Marianjoy Rehabilitation ... with arm and hand impairments by acquiring the ... Oakbrook Terrace network site. , Secured through grant ... a highly-regarded treatment option for patients with upper ... Marianjoy becomes one of just four Illinois providers ...
Breaking Biology Technology:Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 2Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 3Traverse Biosciences Executes Agreement with Aratana Therapeutics to Advance Development of TRB-N0224 for the Treatment and Control of Periodontal Disease in Pets 4Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4Elsevier's Free MOOC Prepares Med Students for Licensing Exam 2Elsevier's Free MOOC Prepares Med Students for Licensing Exam 3Marianjoy Acquires Armeo®Spring Arm and Hand Rehabilitation Exoskeleton at Oakbrook Terrace Facility 2
... , , Gene Provides Yield Stability During Periods of ... June 9, 2009 Monsanto Company (NYSE: MON ) ... help corn plants combat drought conditions and confer yield stability during ... stated that they will use the gene in their first-generation drought-tolerant ...
... Calif., June 9 STAAR Surgical Company (Nasdaq: ... of minimally invasive ophthalmic products, today announced that it ... Hydrophobic Acrylic Injector for use in minimally invasive cataract ... to market this foldable intraocular (IOL) KS-X lens delivery ...
... Collaborate on Testing OVAR Effectiveness , , PITTSBURGH, ... www.neuro-kinetics.com ), manufacturers of noninvasive medical evaluation equipment ... other disorders, said today that the University of ... Center has purchased and installed its I-Portal(R) NOTC (Neuro-Otologic ...
Cached Biology Technology:Monsanto, BASF Scientists Disclose Discovery of Gene Conferring Drought Tolerance in Corn Plants 2Monsanto, BASF Scientists Disclose Discovery of Gene Conferring Drought Tolerance in Corn Plants 3Monsanto, BASF Scientists Disclose Discovery of Gene Conferring Drought Tolerance in Corn Plants 4Monsanto, BASF Scientists Disclose Discovery of Gene Conferring Drought Tolerance in Corn Plants 5STAAR Surgical Receives CE Mark Approval for KS-X Preloaded Hydrophobic Acrylic Lens Injector System 2STAAR Surgical Receives CE Mark Approval for KS-X Preloaded Hydrophobic Acrylic Lens Injector System 3STAAR Surgical Receives CE Mark Approval for KS-X Preloaded Hydrophobic Acrylic Lens Injector System 4University of Michigan Installs Neuro Kinetics' I-Portal(R) NOTC System 2University of Michigan Installs Neuro Kinetics' I-Portal(R) NOTC System 3
(Date:3/24/2015)... , Mar. 24, 2015 Research and Markets ... the "Global Iris Recognition Market 2015-2019" report ... Global Iris Recognition market to grow at a CAGR ... This report covers the present scenario and the growth ... period 2015-2019. To calculate the market size, the report ...
(Date:3/24/2015)... --  NexID Biometrics LLC, whose spoof-mitigation technology boosts ... the beginning of shipments of version 2.0 of its ... based in Potsdam, N.Y. , is ... began here today at the Walter E. Washington Convention ... SDK boosts the accuracy rate range to 96.5 to ...
(Date:3/23/2015)... BOSTON, Mass , March 23, 2015 SoundView ... shipment of NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView ... world user feedback on their experience with the Wocket in ... experience at CVS, Whole Foods and other retailers, making both ... Kris Tuttle also says, "If the company meets ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
... public expects businesses outside the health industry such ... involved in health in ways that go well beyond ... Health Engagement Barometer 2010. Nearly three-quarters (72 percent) ... engaged in health and two-thirds (65 percent) either recommend ...
... the leading cause of death globally and a tremendous ... or clogging of arteries and other blood vessels before ... Institutes for Health (NIH), researchers from Virginia Tech and ... tomography (CT) architectures and methods, including a newly patented ...
... , WEST LAFAYETTE, Ind. - New research findings suggest ... a pulsed laser and tiny metallic "nanocages" might enable ... The system works by shining near-infrared laser pulses through ... - made of an alloy of gold and silver ...
Cached Biology News:Global study shows 'health' joins 'green' as business strategy 2Global study shows 'health' joins 'green' as business strategy 3Global study shows 'health' joins 'green' as business strategy 4New patented technology for improving cardiac CTs receives NIH support 2New patented technology for improving cardiac CTs receives NIH support 3New patented technology for improving cardiac CTs receives NIH support 4New patented technology for improving cardiac CTs receives NIH support 5Ultrasensitive imaging method uses gold-silver 'nanocages' 2
TNF-R2 (L-20)...
Assay Kit formatted for flow cytometric detection of levels of phosphorylated histone H2A.X....
... *SizeSep 400 Spun Columns: For rapid intermediate purification ... - *Prepacked ... containing 0.15% Kathon CG/IcP Biocide. *Remove all ... *Extremely useful in the construction of size-selected ...
{3,8-diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diiodide}. ,250 ug/ml Propidium Iodide (PI) in PBS....
Biology Products: